Association of study characteristics with estimates of effect size in studies of ecstasy use

Journal of Psychopharmacology

Volumn 25, Issue 11, 2011, Pages 1573-1577

  Taylor, Eleanor M ^a   Greene, Natasha M P ^a   Morgan, Celia J A ^b   Munafò, Marcus R ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Bias; ecstasy; prevalence of ecstasy use; year of publication

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE;

ARTICLE; DRUG USE; EFFECT SIZE; HUMAN; LINEAR REGRESSION ANALYSIS; METHODOLOGY; PREVALENCE; PRIORITY JOURNAL; PUBLICATION; STUDY DESIGN;

AMPHETAMINE-RELATED DISORDERS; CLINICAL TRIALS AS TOPIC; HALLUCINOGENS; HUMANS; LINEAR MODELS; META-ANALYSIS AS TOPIC; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; RESEARCH DESIGN; STREET DRUGS;

EID: 83455205704     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881111408955     Document Type: Article

References (17)

1. Cole JC, Sumnall HR, Grob CS. Sorted: Ecstasy facts and fiction. Psychologist. 2002 ; 15: 464-467
2. Curran HV. Is MDMA ('Ecstasy') neurotoxic in humans? An overview of evidence and of methodological problems in research. Neuropsychobiology. 2000 ; 42: 34-41 (Pubitemid 30436314)
3. Degenhardt L, Hall W The Health and Psychological Effects of 'Ecstasy' (MDMA) Use. NDARC Monograph No. 62. Sydney: National Drug and Alcohol Research Centre, University of New South Wales ; 2010 :
4. Gouzoulis-Mayfrank E, Daumann J. The confounding problem of polydrug use in recreational ecstasy/MDMA users: a brief overview. J Psychopharmacol. 2006 ; 20: 188-193
5. Halpern JH, Sherwood AR, Hudson JI, et al. Residual neurocognitive features of long-term ecstasy users with minimal exposure to other drugs. Addiction. 2011 ; 106: 777-786
6. Ioannidis JP, Ntzani EE, Trikalinos TA, et al. Replication validity of genetic association studies. Nat Genet. 2001 ; 29: 306-309 (Pubitemid 33096456)
7. Krebs TS, Johansen PO, Jerome L, et al. Importance of psychiatric confounding in non-randomized studies of heavy ecstasy users. Psychol Med. 2009 ; 39: 876-878
8. Morgan CJ, Muetzelfeldt L, Muetzelfeldt M, et al. Harms associated with psychoactive substances: findings of the UK National Drug Survey. J Psychopharmacol. 2010 ; 24: 147-153
9. Munafò MR, Attwood AS, Flint J. Bias in genetic association studies: effects of research location and resources. Psychol Med. 2008 ; 38: 1213-1214 (Pubitemid 351950155)
10. Parrott AC. Is ecstasy MDMA? A review of the proportion of ecstasy tablets containing MDMA, their dosage levels, and the changing perceptions of purity. Psychopharmacology (Berl). 2004 ; 173: 234-241 (Pubitemid 38703796)
11. Rogers G, Elston J, Garside R, et al. The harmful health effects of recreational ecstasy: a systematic review of observational evidence. Health Technol Assess. 2009 ; 13 :
12. Tanner-Smith EE. Pharmacological content of tablets sold as 'ecstasy': results from an online testing service. Drug Alcohol Depend. 2006 ; 83: 247-254
13. United Nations Office on Drugs and CrimeWorld Drug Report. 2006Retrieved from: http://www.unodc.org/unodc/en/data-and-analysis/WDR-2006.html (accessed 8 April 2011).
14. Verheyden SL, Maidment R, Curran HV. Quitting ecstasy: an investigation of why people stop taking the drug and their subsequent mental health. J Psychopharmacol. 2003 ; 17: 371-378 (Pubitemid 38076331)
15. Vogels N, Brunt TM, Rigter S, et al. Content of ecstasy in the Netherlands: 1993-2008. Addiction. 2009 ; 104: 2057-2066
16. Wang J, Carlson RG, Falck RS, et al. Respondent-driven sampling to recruit MDMA users: a methodological assessment. Drug Alcohol Depend. 2005 ; 78: 147-157 (Pubitemid 40544602)
17. WinstockARThe Mixmag Drugs Survey. 2010Retrieved from: http://www.mixmag-online.com/feb-2010 (accessed 8 April 2011)..